STAT order: Should patients with chronic liver disease be prescribed statins to prevent fibrosis progression and hepatocellular carcinoma?
Juan G. Abraldes, Kelly W. Burak – 4 March 2016
Reply
James Hamilton, Svetlana Lutsenko – 4 March 2016
Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection
Hashem B. El‐Serag, Fasiha Kanwal, Peter Richardson, Jennifer Kramer – 4 March 2016 – The long‐term prognosis in terms of risk or predictors of developing hepatocellular carcinoma (HCC) among patients with sustained virological response (SVR) remains unclear. We conducted a retrospective cohort study using data from the Veterans Affairs VA hepatitis C virus (HCV) Clinical Case Registry in patients with positive HCV RNA between October 1999 and August 2009 and follow‐up through December 2010.
Liver X receptors and copper metabolism: New frontiers for the oxysterol receptors
Chiara Gabbi, Marco Bertolotti – 4 March 2016
Interferon lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in hepatitis C virus genotype 3a
Vincent Pedergnana, David Smith, STOP‐HCV Consortium, Paul Klenerman, Eleanor Barnes, Chris C. A. Spencer, M. Azim Ansari – 4 March 2016
Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection
Hashem B. El‐Serag, Fasiha Kanwal, Peter Richardson, Jennifer Kramer – 4 March 2016 – The long‐term prognosis in terms of risk or predictors of developing hepatocellular carcinoma (HCC) among patients with sustained virological response (SVR) remains unclear. We conducted a retrospective cohort study using data from the Veterans Affairs VA hepatitis C virus (HCV) Clinical Case Registry in patients with positive HCV RNA between October 1999 and August 2009 and follow‐up through December 2010.
Aspirin use and the risk of cholangiocarcinoma
Jonggi Choi, Hassan M. Ghoz, Thoetchai Peeraphatdit, Esha Baichoo, Benyam D. Addissie, William S. Harmsen, Terry M. Therneau, Janet E. Olson, Roongruedee Chaiteerakij, Lewis R. Roberts – 3 March 2016 – Whether aspirin use is protective against cholangiocarcinoma (CCA) remains unclear. We determined the association between aspirin use and other risk factors for each CCA subtype individually. In a hospital‐based case‐control study, 2395 CCA cases (1169 intrahepatic, 995 perihilar, and 231 distal) seen at the Mayo Clinic, Rochester, MN, from 2000 through 2014 were enrolled.
Alcoholic hepatitis: Translational approaches to develop targeted therapies
Pranoti Mandrekar, Ramon Bataller, Hidekazu Tsukamoto, Bin Gao – 3 March 2016 – Alcoholic liver disease is a leading cause of liver‐related mortality worldwide. In contrast to recent advances in therapeutic strategies for patients with viral hepatitis, there is a significant lack of novel therapeutic options for patients with alcoholic liver disease. In particular, there is an urgent need to focus our efforts on effective therapeutic interventions for alcoholic hepatitis (AH), the most severe form of alcoholic liver disease.